Although vaccines would be the ideal tool for control, prevention, elimination, and
eradication of many infectious diseases, developing of parasites vaccines such as malaria …

Malaria continues to be a worldwide leading cause of morbidity and mortality, and the
development of an effective malaria vaccine remains a research imperative. Of the multiple …

The RTS, S vaccine has recently been recommended for implementation as a childhood
vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of …

While recent progress has been made in reducing malaria mortality with other interventions,
vaccines are still urgently needed to further reduce the incidence of clinical disease …

In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …

Abstract Background The RTS, S malaria vaccine is currently undergoing phase 3 trials.
High vaccine-induced antibody titres to the circumsporozoite protein (CSP) antigen have …

Background Malaria is a leading cause of morbidity and mortality worldwide. We previously
reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified …

Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …

Background Seasonal vaccination with the RTS, S/AS01 E vaccine combined with seasonal
malaria chemoprevention (SMC) prevented malaria in young children more effectively than …